Patents by Inventor John Hartney

John Hartney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pulmonary disease treatment and diagnosis based on Arhgef1
    Patent number: 9820951
    Abstract: Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease, Arhgef1, a leukocyte signaling molecule, functions normally to suppress integrin-mediated MMP production by alveolar macrophages. MMP9 production by fibronectin-stimulated monocytes and macrophages depends on autocrine thromboxane receptor signaling and this signaling pathway is attenuated by Arhgef1. Expression of ARHGEF1 by human peripheral blood monocytes varies between individuals and inversely correlates with fibronectin-mediated MMP9 production. Arhgef1 levels can function as a predictor for a pulmonary disease candidate and a thromboxane receptor antagonist can treat a pulmonary disease condition resulting from low Arhgef1 levels.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: November 21, 2017
    Assignees: NATIONAL JEWISH HEALTH, A NON-PROFIT ORGANIZATION, THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Raul M. Torres, John Hartney, Roberta Pelanda
  • PULMONARY DISEASE TREATMENT AND DIAGNOSIS BASED ON ARHGEF1
    Publication number: 20130289121
    Abstract: Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease, Arhgef1, a leukocyte signaling molecule, functions normally to suppress integrin-mediated MMP production by alveolar macrophages. MMP9 production by fibronectin-stimulated monocytes and macrophages depends on autocrine thromboxane receptor signaling and this signaling pathway is attenuated by Arhgef1. Expression of ARHGEF1 by human peripheral blood monocytes varies between individuals and inversely correlates with fibronectin-mediated MMP9 production. Arhgef1 levels can function as a predictor for a pulmonary disease candidate and a thromboxane receptor antagonist can treat a pulmonary disease condition resulting from low Arhgef1 levels.
    Type: Application
    Filed: January 13, 2012
    Publication date: October 31, 2013
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Raul M. Torres, John Hartney, Roberta Pelanda